Table 1 Clinicopathological parameters of patients with SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression
Category | No. of case | Expression | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SCP3 | VEGF-A | VEGF-B | VEGF-C | VEGF-D | ||||||||||||
Low, n (%) | High, n (%) | P | Low, n (%) | High, n (%) | P | Low, n (%) | High, n (%) | P | Low, n (%) | High, n (%) | P | Low, n (%) | High, n (%) | P | ||
Total | 89 | 65 (73) | 24 (27) | Â | 67 (75) | 22 (25) | Â | 62 (70) | 27 (30) | Â | 62 (70) | 27 (30) | Â | 65 (73) | 24 (27) | Â |
Gender | Â | Â | Â | 0.24 | Â | Â | 0.51 | Â | Â | 0.83 | Â | Â | 0.76 | Â | Â | 0.24 |
 Male | 64 | 49 (76) | 15 (24) |  | 47 (73) | 17 (27) |  | 45 (70) | 19 (30) |  | 44 (69) | 20 (31) |  | 49 (77) | 15 (23) |  |
 Female | 25 | 16 (64) | 9 (36) | 20 (80) | 5 (20) | 17 (68) | 8 (32) | 18 (72) | 7 (28) | 16 (64) | 9 (36) | |||||
Age (year) | Â | Â | Â | 0.69 | Â | Â | 0.13 | Â | Â | 0.76 | Â | Â | 0.40 | Â | Â | 0.89 |
 <60 | 25 | 19 (76) | 6 (24) |  | 16 (64) | 9 (36) |  | 44 (69) | 20 (31) |  | 19 (76) | 6 (24) |  | 18 (72) | 7 (28) |  |
 ≥60 | 64 | 46 (72) | 18 (28) | 51 (80) | 13 (20) | 18 (72) | 7 (28) | 43 (67) | 21 (33) | 47 (73) | 17 (27) | |||||
Smoking | Â | Â | Â | 0.31 | Â | Â | 0.30 | Â | Â | 0.77 | Â | Â | 0.14 | Â | Â | 0.58 |
 Never | 19 | 20 (100) | 0 (0) |  | 11 (58) | 6 (42) |  | 11 (58) | 8 (42) |  | 17 (89) | 2 (11) |  | 16 (84) | 3 (16) |  |
 Ever | 29 | 28 (97) | 1 (3) | 21 (72) | 8 (28) | 18 (62) | 11 (38) | 21 (72) | 8 (28) | 26 (90) | 3 (10) | |||||
Stage | Â | Â | Â | 0.18 | Â | Â | 0.66 | Â | Â | 0.60 | Â | Â | 0.68 | Â | Â | 0.56 |
 II | 40 | 32 (80) | 8 (20) |  | 31 (78) | 9 (22) |  | 29 (73) | 11 (28) |  | 27 (68) | 13 (32) |  | 28 (70) | 12 (30) |  |
 III–IV | 49 | 33 (67) | 16 (33) | 46 (73) | 13 (27) | 33 (67) | 16 (33) | 35 (71) | 14 (29) | 37 (76) | 12 (24) | |||||
T stage | Â | Â | Â | 0.49 | Â | Â | 0.64 | Â | Â | 0.32 | Â | Â | 0.78 | Â | Â | 0.22 |
 T1 | 15 | 12 (80) | 3 (20) |  | 12 (80) | 3 (20) |  | 12 (80) | 3 (20) |  | 10 (67) | 5 (33) |  | 9 (60) | 6 (40) |  |
 T2–4 | 74 | 53 (72) | 21 (28) | 55 (74) | 19 (26) | 50 (68) | 24 (32) | 52 (70) | 22 (30) | 56 (76) | 18 (24) | |||||
Tumor type | Â | Â | Â | 0.18 | Â | Â | 0.95 | Â | Â | 0.33 | Â | Â | 0.16 | Â | Â | 0.02 |
 AD | 53 | 36 (68) | 17 (32) |  | 40 (75) | 13 (25) |  | 39 (74) | 14 (26) |  | 34 (64) | 19 (36) |  | 34 (64) | 19 (36) |  |
 SCC | 36 | 29 (81) | 7 (19) | 27 (75) | 9 (25) | 23 (64) | 13 (36) | 28 (78) | 8 (22) | 31 (86) | 5 (14) | |||||